- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to...
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron®...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.61 | -47.2140762463 | 3.41 | 3.76 | 1.62 | 55160 | 2.47675748 | CS |
4 | -2.08 | -53.6082474227 | 3.88 | 5.15 | 1.62 | 50977 | 3.83989431 | CS |
12 | -1.75 | -49.2957746479 | 3.55 | 5.29 | 1.62 | 118861 | 3.93442883 | CS |
26 | -1.75 | -49.2957746479 | 3.55 | 5.29 | 1.62 | 118861 | 3.93442883 | CS |
52 | -1.75 | -49.2957746479 | 3.55 | 5.29 | 1.62 | 118861 | 3.93442883 | CS |
156 | -1.75 | -49.2957746479 | 3.55 | 5.29 | 1.62 | 118861 | 3.93442883 | CS |
260 | -1.75 | -49.2957746479 | 3.55 | 5.29 | 1.62 | 118861 | 3.93442883 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.